Obese men were more likely to have precancerous lesions detected in their benign prostate biopsies compared with nonobese men, and they were at a greater risk for subsequently developing prostate cancer, according to a new study.
The FDA has approved Xofigo (radium Ra 223 dichloride; Bayer) for the treatment of symptomatic late-stage castration-resistant prostate cancer with bone metastases.
Significant associations seen in men's urinary and sexual function based on surgeon performing radical prostatectomy.
A new analysis has found that the loss or amplification of particular DNA regions contributes to the development of prostate cancer, and that patients with two of these DNA changes have a high likelihood of dying from the disease.
Patients with metastatic prostate cancer who visit ER over the weekend have increased odds of death, compared with weekday visits.
According to a recent retrospective study, the protein VEGF does not appear to have any prognostic or predictive value for men with locally advanced prostate cancer.
Sequencing of 57 prostate cancer genomes found that cancer gains a powerful advantage with abrupt intervals of complex, large-scale DNA reshuffling. This process has been dubbed punctuated cancer evolution.
New guidelines from the American Urological Association advise men aged 55 to 69 years who are considering prostate cancer screening to talk with their doctors about the benefits and harms of testing.
Many older men who are found to have prostate cancer after PSA screening receive treatment despite advancing age, poor health, or low-risk disease.
Hereditary mutations in the BRCA2 gene predispose patients to a worse evolution of prostate cancer and a greater risk of developing metastasis.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|